- Home
- DATS vs BIAF Comparison
DATS vs BIAF Comparison
Compare DATS & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DATS
- BIAF
- Stock Information
- Founded
- DATS 2014
- BIAF 2014
- Country
- DATS United States
- BIAF United States
- Employees
- DATS N/A
- BIAF N/A
- Industry
- DATS Computer Software: Prepackaged Software
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- DATS Technology
- BIAF Health Care
- Exchange
- DATS Nasdaq
- BIAF Nasdaq
- Market Cap
- DATS 10.4M
- BIAF 12.2M
- IPO Year
- DATS 2021
- BIAF 2022
- Fundamental
- Price
- DATS $2.60
- BIAF $0.30
- Analyst Decision
- DATS
- BIAF Hold
- Analyst Count
- DATS 0
- BIAF 1
- Target Price
- DATS N/A
- BIAF N/A
- AVG Volume (30 Days)
- DATS 373.1K
- BIAF 11.2M
- Earning Date
- DATS 08-13-2025
- BIAF 08-13-2025
- Dividend Yield
- DATS N/A
- BIAF N/A
- EPS Growth
- DATS N/A
- BIAF N/A
- EPS
- DATS N/A
- BIAF N/A
- Revenue
- DATS $388.00
- BIAF $8,809,228.00
- Revenue This Year
- DATS N/A
- BIAF N/A
- Revenue Next Year
- DATS N/A
- BIAF $20.00
- P/E Ratio
- DATS N/A
- BIAF N/A
- Revenue Growth
- DATS N/A
- BIAF 78.40
- 52 Week Low
- DATS $1.01
- BIAF $0.16
- 52 Week High
- DATS $9.34
- BIAF $2.99
- Technical
- Relative Strength Index (RSI)
- DATS 48.99
- BIAF 50.96
- Support Level
- DATS $2.54
- BIAF $0.22
- Resistance Level
- DATS $2.80
- BIAF $0.46
- Average True Range (ATR)
- DATS 0.26
- BIAF 0.04
- MACD
- DATS -0.02
- BIAF 0.01
- Stochastic Oscillator
- DATS 12.39
- BIAF 30.51
About DATS DatChat Inc.
DatChat Inc is a blockchain, cybersecurity, and social media company that not only focuses on protecting privacy on personal devices, but also protects user information after it is shared with others. Its mobile messaging application is called DatChat Messenger which is a free messaging application. The platform allows users to exercise control over their messages and posts.
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.